Acurx Pharmaceuticals (NASDAQ:ACXP) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Acurx Pharmaceuticals (NASDAQ:ACXP) issued its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11), FiscalAI reports.

Here are the key takeaways from Acurx Pharmaceuticals’ conference call:

• Acurx began enrolling patients in its fully funded, 20-patient PATHFINDER trial for multiply recurrent C. difficile infection in September. Management expects an enrollment update after completion, potentially in the second half of 2027.
• The FDA is open to further discussion of whether data from PATHFINDER and the planned ASPIRE Phase III study could support an NDA; it has not confirmed an approval pathway. Depending on PATHFINDER results and funding, Acurx may pursue a follow-on recurrent-infection trial under the LPAD pathway, while continuing to consider ASPIRE.
• Acurx ended the quarter with $9.7 million in cash and said it has 12 months of funds, which management believes can cover PATHFINDER if enrollment is completed by the third quarter of 2027. The company may need additional financing through equity or other sources, and reported a quarterly net loss of $2.6 million, up from $2.0 million a year earlier.
• Management said partnering discussions are active but none are at a stage for public disclosure, and it is pursuing grants and other funding for its Phase III program. The company’s proposed PATHFINDER 2 could involve about 350 patients and take 18–24 months to enroll, but its design, cost, and regulatory prospects remain uncertain.

Acurx Pharmaceuticals Stock Up 4.2%

NASDAQ ACXP opened at $1.03 on Friday. Acurx Pharmaceuticals has a fifty-two week low of $0.95 and a fifty-two week high of $7.54. The business has a fifty day moving average of $1.22 and a 200-day moving average of $1.91. The stock has a market cap of $5.70 million, a price-to-earnings ratio of -0.38 and a beta of -2.08.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ACXP. HC Wainwright restated a “buy” rating on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.